{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:31:51Z","timestamp":1770971511451,"version":"3.50.1"},"reference-count":32,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1136\/bjophthalmol-2012-302973","type":"journal-article","created":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T04:44:24Z","timestamp":1378961064000},"page":"1447-1450","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":62,"title":["Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome"],"prefix":"10.1136","volume":"97","author":[{"given":"Jose M","family":"Ruiz-Moreno","sequence":"first","affiliation":[]},{"given":"Luis","family":"Arias","sequence":"additional","affiliation":[]},{"given":"Javier A","family":"Montero","sequence":"additional","affiliation":[]},{"given":"Angela","family":"Carneiro","sequence":"additional","affiliation":[]},{"given":"Rufino","family":"Silva","sequence":"additional","affiliation":[]}],"member":"239","published-online":{"date-parts":[[2013,9,11]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2012-302973-1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial\u2014VIP report no. 1","volume":"108","author":"Verteporfin in Photodynamic Therapy Study Group.","year":"2001","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2012-302973-2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/IAE.0b013e3181c9691e","article-title":"Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results","volume":"30","author":"Silva","year":"2010","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2012-302973-3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajo.2008.07.017","article-title":"Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results","volume":"147","author":"Ikuno","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-4","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bjo.2005.066431","article-title":"Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia","volume":"89","author":"Nguyen","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.2008.145391","article-title":"Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome","volume":"93","author":"Ruiz-Moreno","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.2006.099887","article-title":"Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia","volume":"91","author":"Sakaguchi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/IAE.0b013e3182278bae","article-title":"Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia","volume":"32","author":"Hayashi","year":"2012","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2012-302973-8","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/bjophthalmol-2012-301639","article-title":"Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia","volume":"96","author":"Gharbiya","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-9","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2012-302973-10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/eye.2012.97","article-title":"Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization","volume":"26","author":"Lai","year":"2012","journal-title":"Eye (Lond)"},{"key":"key-10.1136\/bjophthalmol-2012-302973-11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0032-1328366","article-title":"Three Years Follow-up Results of Ranibizumab Treatment for Choroidal Neovascularization Secondary to Pathologic Myopia","volume":"230","author":"Hefner","year":"2013","journal-title":"Klin Monbl Augenheilkd"},{"key":"key-10.1136\/bjophthalmol-2012-302973-12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jcjo.2011.12.009","article-title":"Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results","volume":"47","author":"Peiretti","year":"2012","journal-title":"Can J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-13","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1111\/j.1755-3768.2010.02070.x","article-title":"Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization","volume":"90","author":"Ruiz-Moreno","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-14","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bjo.2009.166025","article-title":"Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation","volume":"94","author":"Baba","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization","volume":"141","author":"Tong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1755-3768.2009.01717.x","article-title":"Vascular endothelial growth factor in the aqueous humour in eyes with myopic choroidal neovascularization","volume":"89","author":"Sawada","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-17","first-page":"2265","article-title":"Aqueous humor concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in high myopic patients","volume":"18","author":"Shin","year":"2012","journal-title":"Mol Vis"},{"key":"key-10.1136\/bjophthalmol-2012-302973-18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bjo.2006.096776","article-title":"Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia","volume":"91","author":"Yamamoto","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/bjo.2008.145797","article-title":"Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study","volume":"93","author":"Chan","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ajo.2008.07.022","article-title":"Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results","volume":"147","author":"Gharbiya","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-21","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.ophtha.2007.03.043","article-title":"Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study","volume":"114","author":"Chan","year":"2007","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2012-302973-22","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/IAE.0b013e3181e22659","article-title":"Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization","volume":"30","author":"Ruiz-Moreno","year":"2010","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2012-302973-23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1055\/s-0031-1273210","article-title":"[Results of ranibizumab treatment for choroidal neovascularization secondary to pathological myopia]","volume":"228","author":"Hefner","year":"2011","journal-title":"Klin Monbl Augenheilkd"},{"key":"key-10.1136\/bjophthalmol-2012-302973-24","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajo.2009.03.026","article-title":"Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy","volume":"148","author":"Hayashi","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ajo.2009.08.008","article-title":"Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization","volume":"149","author":"Ikuno","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-26","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.ophtha.2011.07.029","article-title":"Myopic choroidal neovascularization","volume":"118","author":"Ruiz-Moreno","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2012-302973-27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/IAE.0b013e3181bd2fe4","article-title":"Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization","volume":"30","author":"Yoon","year":"2010","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2012-302973-28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2012-302973-29","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00417-010-1340-y","article-title":"Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome","volume":"248","author":"Ruiz-Moreno","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302973-30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/jop.2011.0023","article-title":"Intravitreal injection of 2.5\u2005mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up","volume":"27","author":"Chen","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"key-10.1136\/bjophthalmol-2012-302973-31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","article-title":"Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration","volume":"120","author":"Ying","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2012-302973-32","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/bjo.2008.147611","article-title":"Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab","volume":"93","author":"Ruiz-Moreno","year":"2009","journal-title":"Br J Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2012-302973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:43:55Z","timestamp":1601109835000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2012-302973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,11]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,10,18]]},"published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1136\/bjophthalmol-2012-302973"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302973","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,11]]}}}